Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Net Asset Value(s)

12 Jul 2022 07:00

RNS Number : 0911S
CATCo Reinsurance Opps Fund Ltd
12 July 2022
 

FOR IMMEDIATE RELEASE

 

 

12 July 2022

CATCo Reinsurance Opportunities Fund Ltd. (the "Company")

Net Asset Value

 

 

To: SFS, London Stock Exchange and Bermuda Stock Exchange

March 2022 Net Asset Values

Markel CATCo Investment Management Ltd., the Company's Investment Manager, announces the following unaudited Net Asset Value ("NAV") of the Company's Ordinary Shares and C Shares as at the close of business on 31 March 2022.

 

Ordinary Shares

 

· Total NAV (USD): $53,593,211

· NAV per Share of $0.3590 (based on the number of Ordinary Shares in issue as at 31 March 2022)

· Adjusted NAV per Share of $1.2493 (based on the number of Ordinary Shares in issue post the partial compulsory redemption of shares, as announced on 7th April 2022)

 

 

The adjusted Ordinary Share NAV (after taking into account the April 2022 partial compulsory redemption) consists of approximately $1.1m of cash on hand and approximately $0.75m of investments held in Side Pocket Investments.

 

C Shares

 

· Total NAV (USD): $61,196,987

· NAV per Share of $0.7353 (based on the number of C Shares in issue as at 31 March 2022)

· Adjusted NAV per Share of $8.8185 (based on the number of C Shares in issue post the partial compulsory redemption of shares as announced on 7th April 2022)

 

 

The adjusted C Share NAV (after taking into account the April 2022 partial compulsory redemption) consists of approximately $4.2m of cash on hand and approximately $3.1m of investments held in Side Pocket Investments.

 

 

 

 

For further information:

 

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGPUMGMUPPPUG
Date   Source Headline
29th Mar 201111:40 amRNSIssue of Equity
29th Mar 201111:36 amRNSDirector/PDMR Shareholding
7th Mar 20111:49 pmRNSNet Asset Value(s)
7th Feb 20118:30 amRNSPortfolio Update
7th Feb 20118:11 amRNSNet Asset Value(s)
14th Jan 20117:00 amRNSPortfolio Update
7th Jan 20113:33 pmRNSHolding(s) in Company
23rd Dec 201011:00 amRNSHolding(s) in Company
20th Dec 20107:00 amRNSResult of Placing and Admission to SFM
13th Jul 20064:12 pmRNSHolding(s) in Company
10th Jul 20063:20 pmRNSHolding(s) in Company
7th Jul 20062:51 pmRNSOffer for Cambridge Antibody
3rd Jul 20064:56 pmRNSDirectorate Change
30th Jun 20064:12 pmRNSHolding(s) in Company
30th Jun 20064:06 pmRNSDelisting
30th Jun 200610:27 amRNSAdditional Listing
30th Jun 20067:02 amRNSOffer for Cambridge Antibody
27th Jun 20062:26 pmRNSHolding(s) in Company
27th Jun 200612:34 pmRNSHolding(s) in Company
23rd Jun 20062:25 pmRNSAppointment of Directors
22nd Jun 20063:07 pmRNSRule 8.3- CAT
22nd Jun 200611:31 amRNSCAT Limited appoints new CE
22nd Jun 200611:11 amRNSEPT Disclosure
22nd Jun 200611:09 amRNSEPT Disclosure
22nd Jun 20067:02 amRNSOffer for Cambridge Antibody
21st Jun 20065:11 pmRNSRule 8.1- C.A.T.
21st Jun 200611:30 amRNSEPT Disclosure
21st Jun 200610:20 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
19th Jun 20063:25 pmRNSRule 8.3 - Cambridge Antibody
19th Jun 20061:07 pmRNSRule 8.3- (CAT)
19th Jun 200611:30 amRNSEPT Disclosure
19th Jun 200611:23 amRNSEPT Disclosure
19th Jun 200610:33 amRNSEPT Disclosure
16th Jun 200611:45 amRNSEPT Disclosure
16th Jun 200611:24 amRNSEPT Disclosure
16th Jun 200611:08 amRNSEPT Disclosure
15th Jun 20065:01 pmRNSEPT Disclosure
15th Jun 20062:48 pmRNSRule 8.3- (CAT)
15th Jun 20062:17 pmRNSRule 2.10 Announcement
15th Jun 200612:45 pmRNSEPT Disclosure
15th Jun 200611:36 amRNSEPT Disclosure
14th Jun 20063:38 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20063:05 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20061:43 pmRNSRule 8.3- (CAT)
14th Jun 200611:36 amRNSEPT Disclosure
14th Jun 200611:15 amRNSEPT Disclosure
14th Jun 200610:59 amRNSEPT Disclosure
14th Jun 200610:23 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.